Analysis of Antitumor Drugs Used in 25 Hospitals in Chengdu Area from 2014 to 2016
Zhao Xueli;Zheng Yongchi;Li Xiaomei;Dujiangyan People’s Hospital;
Objective To evaluate the rationality of the application of antitumor drugs in the hospitals in Chengdu area. Methods The sales amount,DDDs and DDC of antitumor drugs used in 25 hospitals in Chengdu area from 2014 to 2016 were comprehensive analyzed. Results Over the past 3 years,the total sales amount of antitumor drugs was 694 016 000 Yuan,618 574 100 Yuan and688 896 000 Yuan,respectively. Among the DDDs,other antitumor drugs ranked the first for a long time and increased steadily,and antitumor hormone drugs were ranked the second in substitution of antimetabolic drugs. Among the top 15 antitumor drugs in terms of sales,the sales amount of imatinib was increasing year by year,gradually rising to the first,the DDDs of Huisheng ranked the first because of low DDC. Conclusion The current situation of antitumor drugs used in Chengdu area from 2014 to 2016 was basically consistent with the incidence of cancer in China and the selection of treatment options for antitumor drugs. Drug price is still an important factor restricting the selection of clinical drugs. Just reducing the price of antitumor drugs can not alleviate the development trend of cancer in China. The clinical application of the Chinese patent drugs is still to be further standardized.
【CateGory Index】： R95